| Literature DB >> 29061246 |
Michael J Bradshaw1, Tracey A Cho2, Felicia C Chow3.
Abstract
Patients on immunosuppressive therapy for rheumatic diseases are at increased risk of infection. Although infections of the central nervous system (CNS) are less common compared with other sites, patients on broadly immunosuppressive and biologic immunomodulatory agents may be susceptible to more severe, disseminated forms of infection, including of the CNS. Certain key principles regarding infection risk apply across immunosuppressive therapies, including increased risk with higher doses and longer duration of therapy and with combination therapy. Providers should be aware of the CNS infection risk related to immunosuppressant use to help guide best practices for screening and prophylaxis.Entities:
Keywords: Central nervous system infection; Immunomodulatory therapy; Immunosuppression; Rheumatic disease
Mesh:
Substances:
Year: 2017 PMID: 29061246 PMCID: PMC5679400 DOI: 10.1016/j.rdc.2017.06.009
Source DB: PubMed Journal: Rheum Dis Clin North Am ISSN: 0889-857X Impact factor: 2.670